Sustained release of metformin via red blood cell accumulated sulfenamide prodrug

Journal of Pharmaceutical Sciences

Volumn 103, Issue 7, 2014, Pages 2207-2210

  Peura, Lauri ^a   Huttunen, Kristiina M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

blood flow; controlled release; drug delivery systems; preclinical pharmacokinetics; prodrugs

Indexed keywords

METFORMIN; PRODRUG; SULFENAMIDE DERIVATIVE; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; SULFAMERAZINE; SULFENAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; ERYTHROCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA HALF LIFE; RAT; SUSTAINED DRUG RELEASE; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HALF-LIFE; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; METFORMIN; PRODRUGS; RATS; SULFAMERAZINE; TIME FACTORS;

EID: 84903182010     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24040     Document Type: Article

References (18)

1. Davidson MB, Peters AL,. 1997. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 102 (1): 99-110. (Pubitemid 27089992)
2. Kirpichnikov D, McFarlane SI, Sowers JR,. 2002. Metformin: An update. Ann Intern Med 137 (1): 25-33. (Pubitemid 34705373)
3. Rojas LB, Gomes MB,. 2013. Metformin: An old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 5 (6): 1-15.
4. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF,. 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12 (2): 235-246. (Pubitemid 11034446)
5. Campbell RK, White JR Jr., Saulie BA,. 1996. Metformin: A new oral biguanide. Clin Ther 18 (3): 360-371. (Pubitemid 26248896)
6. Lalau JD, Lacroix C,. 2003. Measurement of metformin concentration in erythrocytes: Clinical implications. Diabetes Obes Metab 5 (2): 93-98. (Pubitemid 36372500)
7. Robert F, Fendri S, Hary L, Lacroix C, Andrejak M, Lalau JD,. 2003. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 29 (3): 279-283. (Pubitemid 36807438)
8. Hinderling PH., 1997. Red blood cells: A neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49 (3): 279-295. (Pubitemid 27414916)
9. Chambers E, Mitragotri S,. 2007. Long circulating nanoparticles via adhesion on red blood cells: Mechanism and extended circulation. Exp Biol Med 232 (7): 958-966. (Pubitemid 47026803)
10. Wolfe AL, Duncan KK, Parelkar NK, Weir SJ, Vielhauer GA, Boger DL,. 2012. A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct. J Med Chem 55 (12): 5878-5886.
11. Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ,. 2012. Lisdexamfetamine and immediate release d-amfetamine-Differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology 63 (6): 1064-1074.
12. Sitar DS,. 1996. Clinical pharmacokinetics of bambuterol. Clin Pharmacokinet 31 (4): 246-256. (Pubitemid 26340660)
13. Huttunen KM, Mannila A, Laine K, Kemppainen E, Leppanen J, Vepsalainen J, Jarvinen T, Rautio J,. 2009. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem 52 (14): 4142-4148.
14. Huttunen KM, Leppanen J, Vepsalainen J, Sirvio J, Laine K, Rautio J,. 2012. In vitro and in vivo evaluation of a sulfenamide prodrug of basic metformin. J Pharm Sci 101 (8): 2854-2860.
15. Ghashghaeinia M, Toulany M, Saki M, Rodemann HP, Mrowietz U, Lang F, Wieder T,. 2011. Potential roles of the NFkappaB and glutathione pathways in mature human erythrocytes. Cell Mol Biol Lett 17 (1): 11-20.
16. Nti-Addae KW, Guarino VR, Dalwadi G, Stella VJ,. 2012. Determination of the permeability characteristics of two sulfenamide prodrugs of linezolid across Caco-2 cells. J Pharm Sci 101 (9): 3134-3141.
17. Nti-Addae KW, Laurence JS, Skinner AL, Stella VJ,. 2011. Reversion of sulfenamide prodrugs in the presence of free thiol-containing proteins. J Pharm Sci 100 (7): 3023-3027.
18. Piomelli S,. 1981. Chemical toxicity of red cells. Environ Health Perspect 39: 65-70.